Single-Center Outcomes of WATCHMAN™ Implantation with Comparison to Oral Anticoagulant and Dual Antiplatelet Therapy

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Nov 29

PMID 38021921

Authors

Francis Demiraj

Michael S Benrubi

Denis Babici

Eti Muharremi

Ronald Pachon

Ahmed Osman

Affiliations

Soon will be listed here.

Abstract

Background The WATCHMAN™ device is a Food and Drug Administration (FDA)-approved device that reduces the risk of stroke from atrial fibrillation (AF) in those who have a contraindication to taking oral anticoagulation. A key aspect of this device implantation is the choice of medical therapy in the months after device implantation with Vitamin K antagonist oral anticoagulants (OAC) being the mainstay of therapy but dual antiplatelet therapy (DAPT) poses as a potential alternative to patients who have a contraindication to OAC use. Methods Our single-center study retroactively followed 150 patients post-WATCHMAN™ implantation and evaluated outcomes at 12 months post-implantation in two cohorts, those treated with OAC or DAPT. Our results were obtained via chart review of a single-center electronic medical records system. Results In our study, 67.33% of study patients were males and 49.33% were on OAC compared to 36.00% that were on DAPT. Ten patients were not able to undergo device implantation. With this analysis, we found similarly low rates of complications such as stroke and device-associated thrombosis (DAT) in both groups. Our DAPT cohort did have a higher number of gastrointestinal (GI) bleeding but this was not significant in our analysis. Discussion Our study compares to larger trials that show similar outcomes between OAC and DAPT post-implantation of the WATCHMAN™ device. The increased number of GI bleeding in our DAPT cohort could be the result of the underlying advanced age and comorbidity of that patient cohort. Conclusion Our results suggest that DAPT is a safe alternative to OAC for patients undergoing WATCHMAN™ implantation.

References

Friberg L, Benson L, Rosenqvist M, Lip G . Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012; 344:e3522. PMC: 3365143. DOI: 10.1136/bmj.e3522. View

Chan Y, See L, Tu H, Yeh Y, Chang S, Wu L . Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018; 7(8). PMC: 6015442. DOI: 10.1161/JAHA.117.008150. View

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

Reddy V, Doshi S, Sievert H, Buchbinder M, Neuzil P, Huber K . Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6):720-9. DOI: 10.1161/CIRCULATIONAHA.112.114389. View

Pacha H, Hritani R, Alraies M . Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion Using the WATCHMAN Device. Ochsner J. 2018; 18(3):193-194. PMC: 6162133. DOI: 10.31486/toj.18.0012. View

Alkhouli M, Busu T, Shah K, Osman M, Alqahtani F, Raybuck B . Incidence and Clinical Impact of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion: A Meta-Analysis. JACC Clin Electrophysiol. 2018; 4(12):1629-1637. DOI: 10.1016/j.jacep.2018.09.007. View

Chew D, Piccini J . Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty?. Circ Cardiovasc Interv. 2020; 13(7):e009534. DOI: 10.1161/CIRCINTERVENTIONS.120.009534. View

Dukkipati S, Kar S, Holmes D, Doshi S, Swarup V, Gibson D . Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes. Circulation. 2018; 138(9):874-885. DOI: 10.1161/CIRCULATIONAHA.118.035090. View

Bergmann M, Ince H, Kische S, Schmitz T, Meincke F, Schmidt B . Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention. 2018; 13(17):2003-2011. DOI: 10.4244/EIJ-D-17-00672. View

10.

Wintgens L, Maarse M, Swaans M, Rensing B, van Dijk V, Boersma L . The WATCHMAN left atrial appendage closure device for patients with atrial fibrillation: current status and future perspectives. Expert Rev Med Devices. 2020; 17(7):615-626. DOI: 10.1080/17434440.2020.1781615. View

11.

Sondergaard L, Wong Y, Reddy V, Boersma L, Bergmann M, Doshi S . Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN. JACC Cardiovasc Interv. 2019; 12(11):1055-1063. DOI: 10.1016/j.jcin.2019.04.004. View

12.

Reddy V, Mobius-Winkler S, Miller M, Neuzil P, Schuler G, Wiebe J . Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013; 61(25):2551-6. DOI: 10.1016/j.jacc.2013.03.035. View

13.

Lempereur M, Aminian A, Freixa X, Gafoor S, Kefer J, Tzikas A . Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv. 2017; 90(5):E111-E121. DOI: 10.1002/ccd.26903. View

14.

Main M, Fan D, Reddy V, Holmes D, Gordon N, Coggins T . Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial). Am J Cardiol. 2016; 117(7):1127-34. DOI: 10.1016/j.amjcard.2016.01.039. View

15.

Holmes Jr D, Kar S, Price M, Whisenant B, Sievert H, Doshi S . Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1):1-12. DOI: 10.1016/j.jacc.2014.04.029. View